OLMA Olema Pharmaceuticals, Inc.
Healthcare$13.55-0.95%ClosedMarket Cap: $1.18B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.93
P/S
0.00
EV/EBITDA
-5.78
DCF Value
$0.49
FCF Yield
-12.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-46.0%
ROA
-34.9%
ROIC
-41.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-58.0M | $-53.1M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-50.1M | $-46.1M | $— | — |
| FY null | $0.00 | NaN% | $-178.7M | $-162.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-45.9M | $-42.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-47.9M | $-43.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-34.9M | $-30.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-36.8M | $-33.6M | $— | — |
| FY null | $0.00 | NaN% | $-142.3M | $-129.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-37.6M | $-34.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-33.5M | $-30.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-34.3M | $-31.0M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-30.4M | $-26.8M | $-0.49 | — |